Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 2
2006 2
2008 2
2009 5
2010 3
2011 8
2012 10
2013 7
2014 14
2015 13
2016 16
2017 10
2018 8
2019 15
2020 13
2021 14
2022 17
2023 25
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, Soto LMS, Jiang M, Raso MG, Wang S, Bell D, Liu J, Wang H, Tan D, Torres-Cabala C, Gan Q, Wu Y, Albarracin C, Hung MC, Meric-Bernstam F, Wistuba II, Prieto VG, Sahin AA, Ding Q. Ai D, et al. Among authors: huo l. Mod Pathol. 2021 Apr;34(4):710-719. doi: 10.1038/s41379-020-00692-8. Epub 2020 Oct 3. Mod Pathol. 2021. PMID: 33011748 Free article.
TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC, Wang G, Parkinson B, Huo L, Peng Y, Wang J, Salisbury T, Wu Y, Chen H, Albarracin CT, Resetkova E, Middleton LP, Krishnamurthy S, Gan Q, Sun H, Huang X, Shen T, Chen W, Parwani AV, Sahin AA, Li Z, Ding Q. Yoon EC, et al. Among authors: huo l. Hum Pathol. 2022 Jul;125:97-107. doi: 10.1016/j.humpath.2022.04.006. Epub 2022 Apr 9. Hum Pathol. 2022. PMID: 35413381
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Yam C, et al. Among authors: huo l. Clin Cancer Res. 2022 Jul 1;28(13):2878-2889. doi: 10.1158/1078-0432.CCR-21-3100. Clin Cancer Res. 2022. PMID: 35507014 Free PMC article. Clinical Trial.
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
Sun J, Mao F, Liu C, Zhang F, Jiang D, Guo W, Huo L, Zhou L, Lau WY, Shi J, Cheng S. Sun J, et al. Among authors: huo l. Signal Transduct Target Ther. 2023 Sep 27;8(1):368. doi: 10.1038/s41392-023-01604-3. Signal Transduct Target Ther. 2023. PMID: 37752117 Free PMC article. Clinical Trial.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. Yam C, et al. Among authors: huo l. Breast Cancer Res Treat. 2023 Jun;199(3):457-469. doi: 10.1007/s10549-023-06929-9. Epub 2023 Apr 15. Breast Cancer Res Treat. 2023. PMID: 37061619 Clinical Trial.
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer.
Shah VV, Duncan AD, Jiang S, Stratton SA, Allton KL, Yam C, Jain A, Krause PM, Lu Y, Cai S, Tu Y, Zhou X, Zhang X, Jiang Y, Carroll CL, Kang Z, Liu B, Shen J, Gagea M, Manu SM, Huo L, Gilcrease M, Powell RT, Guo L, Stephan C, Davies PJ, Parker-Thornburg J, Lozano G, Behringer RR, Piwnica-Worms H, Chang JT, Moulder SL, Barton MC. Shah VV, et al. Among authors: huo l. Nat Commun. 2021 Sep 10;12(1):5389. doi: 10.1038/s41467-021-25650-z. Nat Commun. 2021. PMID: 34508101 Free PMC article.
Neoadjuvant intensity modulated radiotherapy for a single and small (≤5 cm) hepatitis B virus-related hepatocellular carcinoma predicted to have high risks of microvascular invasion: a randomized clinical trial.
Wei X, Jiang Y, Feng S, Lu C, Huo L, Zhou B, Meng Y, Lau WY, Zheng Y, Cheng S. Wei X, et al. Among authors: huo l. Int J Surg. 2023 Oct 1;109(10):3052-3060. doi: 10.1097/JS9.0000000000000574. Int J Surg. 2023. PMID: 37352528 Free PMC article. Clinical Trial.
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EA. Yam C, et al. Among authors: huo l. Clin Cancer Res. 2021 Oct 1;27(19):5365-5375. doi: 10.1158/1078-0432.CCR-21-0144. Clin Cancer Res. 2021. PMID: 34253579 Free PMC article.
169 results